This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This article will be a weekly roundup of interesting stories, product announcements, new hires, partnerships, research studies, awards, sales, and more. Collaborations between AI vendors and biotech/pharma companies over the last five years are worth more than $45 billion , according to a recent report from Accenture.
You can read more details about this evolving situation in the WSJ article linked above, and other takes in tech, business, and social media that have begun to populate the interwebs. Was this due to the growing experience and reporting of surprise medicalbills? health care. Out-of-network costs?
He co-wrote the first “It’s The Prices Stupid” research article in Health Affairs with Gerard Anderson et. First, a Wall Street Journal profile of Bluebird Bio , a biotech firm that plans to sell gene-replacement therapy extending annual payments to patients based on whether the drug is effective.
Dr. Fendrick was part of a team that wrote one of the first research articles on the effects of increasing patient cost sharing on health disparities — published in 2008 in the Journal of General Internal Medicine. ” Out of the mouths of Mom’s, right?!
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content